Equities
  • Price (USD)44.01
  • Today's Change-1.87 / -4.08%
  • Shares traded691.16k
  • 1 Year change-26.37%
  • Beta1.3891
Data delayed at least 15 minutes, as of Aug 18 2022 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.

  • Revenue in USD (TTM)249.94m
  • Net income in USD-153.93m
  • Incorporated2001
  • Employees329.00
  • Location
    Arrowhead Pharmaceuticals Inc177 E Colorado Blvd, Suite 700PASADENA 91105United StatesUSA
  • Phone+1 (626) 696-4702
  • Fax+1 (626) 304-3401
  • Websitehttps://arrowheadpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Blueprint Medicines Corp230.49m-701.64m4.07bn580.00--5.67--18.39-11.87-11.873.9012.530.16690.8416.71465,630.30-50.82-23.88-56.65-26.4490.76---304.41-96.065.77--0.00---77.3145.34-305.20--5.59--
Alkermes Plc1.17bn-94.15m4.20bn2.21k--3.89--3.59-0.579-0.5797.226.590.60251.494.13530,695.60-4.83-6.82-6.13-8.4781.5383.51-8.02-11.732.03-11.920.2139--13.009.5056.55---8.49--
Beam Therapeutics Inc76.92m-233.99m4.28bn341.00--5.78--60.05-3.41-3.411.1311.380.0666--3.08225,560.10-20.25---23.75-------304.21------0.0052--215,916.70---89.23------
Global Blood Therapeutics Inc234.86m-322.46m4.49bn457.00--37.99--19.20-5.00-5.003.641.760.31620.07829.53513,919.00-43.42-36.17-48.87-39.5598.10---137.30-345.736.17-13.410.831--57.31---22.43--19.05--
Mirati Therapeutics Inc78.16m-644.51m4.57bn413.00--4.15--59.09-11.85-11.851.4520.000.0593--2.28189,256.70-48.91-42.36-55.19-45.89-----824.57-1,299.08----0.00--438.08---62.54--118.65--
Intellia Therapeutics Inc45.34m-400.43m4.59bn485.00--5.74--111.55-5.36-5.360.607211.590.0509--18.7193,484.54-44.92-25.86-50.53-28.70-----883.17-343.23---75.560.00---43.0114.94-99.58--15.65--
Denali Therapeutics Inc112.42m-283.86m4.61bn395.00--5.37--42.28-2.32-2.320.91857.180.0802--13.12295,842.10-20.26-13.07-23.63-14.30-----252.50-100.25----0.00---85.50---508.49--6.74--
Azenta Inc554.87m-28.37m4.79bn2.90k--1.35171.338.37-0.381429.037.4245.710.20232.472.63191,334.50-1.030.6373-1.140.76447.5141.42-5.111.3912.79--0.00369.1632.213.43-9.51--32.670.00
Arrowhead Pharmaceuticals Inc249.94m-153.93m4.81bn329.00--10.94--19.89-1.48-1.482.374.290.3362--549.32759,693.00-20.71-16.34-26.94-19.63-----61.59-55.64----0.00--57.16287.47-66.58--43.59--
Natera Inc723.48m-575.58m4.93bn2.67k--12.05--7.41-6.07-6.077.624.590.754813.184.69270,965.20-60.05-40.13-78.45-55.5846.3843.84-79.56-61.143.46-67.910.4269--59.9724.10-105.32--16.47--
Cytokinetics, Inc.151.15m-215.92m4.94bn253.00--40.67--32.85-2.59-2.591.801.300.2263--64.68597,442.70-32.32-38.05-35.77-41.80-----142.85-352.73---5.260.6416--26.15-7.92-69.15--98.25--
Guardant Health Inc408.13m-551.10m5.00bn1.37k--17.00--13.29-5.41-5.414.013.120.19693.085.48297,254.20-25.69-16.27-27.87-17.8067.4364.51-130.47-85.345.83--0.7807--30.3271.41-59.85--111.67--
10X Genomics Inc497.93m-142.49m5.09bn1.24k--6.82--10.69-1.26-1.264.436.880.50321.847.33401,882.20-14.40---16.30--78.85---28.62--5.05--0.00--64.13--89.27------
Medpace Holdings Inc1.29bn209.02m5.24bn4.80k30.6719.3323.744.265.765.7635.389.140.9237--6.64285,838.4015.039.3129.2012.8628.9830.5416.2713.20--417.580.4685--23.3822.0625.1668.4015.87--
Intra-Cellular Therapies Inc138.45m-321.36m5.31bn512.00--7.73--40.32-3.69-3.691.587.650.19260.75294.45270,416.30-44.71-40.81-48.82-43.8691.08---232.11-853.7510.82--0.00--267.35202.53-25.16--46.09--
Data as of Aug 18 2022. Currency figures normalised to Arrowhead Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

37.11%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 202211.12m10.52%
The Vanguard Group, Inc.as of 30 Jun 20229.80m9.27%
SSgA Funds Management, Inc.as of 31 Mar 20224.68m4.43%
AllianceBernstein LPas of 31 Mar 20222.76m2.61%
Fidelity Management & Research Co. LLCas of 30 Jun 20222.74m2.59%
Invesco Advisers, Inc.as of 31 Mar 20222.01m1.90%
Geode Capital Management LLCas of 30 Jun 20221.85m1.75%
JPMorgan Investment Management, Inc.as of 30 Jun 20221.78m1.69%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 20221.30m1.23%
Credit Suisse Asset Management (Schweiz) AGas of 30 Jun 20221.20m1.13%
More ▼
Data from 31 Mar 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.